Generation of hematopoietic cells from multipotent neural stem cells

• US 6,093,531 A
• Filed: 06/19/1998
• Issued: 07/25/2000
• Est. Priority Date: 09/29/1997
• Status: Expired due to Fees

• Current Assignee: Neurospheres Holding Limited
• Original Assignee: Neurospheres Holding Limited
• Inventors: Bjornson, Christopher R., Reynolds, Brent A., Rietze, Rod L., Vescovi, Angelo L.
• Primary Examiner(s): Brusca, John S.
• Application Number:
  US09/100,679
• Time in Patent Office: 767 Days
• Field of Search: 435/1.1, 435/325, 429/93.1, 429/93.21
• US Class Current: 435/1.1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: C12N 5/0623 Stem cells

Abstract

Multipotent neural stem cell (MNSC) progeny are induced to generate cells of the hematopoietic system by placing the MNSC progeny in a hematopoietic-inducing environment. The hematopoietic-inducing environment can be either ex vivo or in vivo. A mammal'"'"'s circulatory system provides an in vivo environment that can induce xenogeneic, allogeneic, or autologous MNSC progeny to generate a full complement of hematopoietic cells. Transplantation of MNSC progeny provides an alternative to bone marrow and hematopoietic stem cell transplantation to treat blood-related disorders.

Claims

1. A method of generating hematopoietic cells from mammalian multipotent neural stem cell progeny comprising placing said multipotent neural stem cell progeny in an environment that induces said multipotent neural stem cell progeny to produce said hematopoietic cells, wherein said environment comprises a mammal'"'"'s circulatory system and said multipotent neural stem cell progeny are administered to said circulatory system.

2. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from juvenile or adult tissue.

3. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from embryonic or fetal tissue.

4. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from neural tissue selected from the cerebral cortex, frontal lobe, conus medullaris, hypothalamus, cerebellum, midbrain, brainstem, spinal cord, cerebro spinal fluid, and tissues surrounding CNS ventricles.

5. The method of claim 1 wherein prior to administering said multipotent neural stem cell progeny to said circulatory system, said mammal undergoes a treatment to suppress or deplete endogenous hematopoietic cells.

6. The method of claim 5 wherein said treatment is radiation.

7. The method of claim 5 wherein said treatment is chemotherapy.

8. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from said mammal.

9. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from an allogeneic donor.

10. The method of claim 1 wherein said multipotent neural stem cell progeny are derived from a xenogeneic donor.

11. The method of claim 1 wherein said multipotent neural stem cell progeny comprise an enriched population of multipotent neural stem cells.

12. The method of claim 11 wherein said enriched population of multipotent neural stem cells comprises at least 1% multipotent neural stem cells.

13. The method of claim 11 wherein said enriched population of multipotent neural stem cells comprises at least 10% multipotent neural stem cells.

14. A dosage form for generating new hematopoietic cells in a patient comprising a device containing a composition comprising multipotent neural stem cell progeny, wherein said device is suitable for delivering said composition to a patient'"'"'s circulatory system.

15. The dosage form of claim 14, wherein said device comprises a syringe for intravenous injection.

16. The dosage form of claim 14, wherein said device comprises a bag for intravenous infusion.